Home > Oncology > ASCO 2021 > Genitourinary Cancers > Glutaminase inhibitor telaglenastat does not improve survival mRCC

Glutaminase inhibitor telaglenastat does not improve survival mRCC

Presented By
Dr Nizar Tannir, Houston University, TX, USA
Conference
ASCO 2021
Trial
Phase 3, CANTATA
First results of the phase 3 CANTATA trial showed no survival benefit of treatment with the glutaminase inhibitor telaglenastat plus cabozantinib versus cabozantinib alone in patients with previously treated metastatic renal cell cancer (mRCC). Renal cell cancer is a highly metabolic tumour with high expression of glutaminase, a key enzyme in glutamine metabolism. Telaglenastat is a potent glutaminase inhibitor showing promising anti-tumour effect in heavily pretreated mRCC patients when combined with everolimus or cabozantinib [1,2]. The phase 3 CANTATA trial (NCT03428217) evaluated the efficacy and safety of the combination telaglenastat plus cabozantinib in patients with previously treated mRCC. Eligible patients had 1 or 2 prior lines of systemic therapy for mRCC, including at least 1 anti-angiogenic therapy or nivolumab/ipilimumab. A total of 4...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on